Glenmark Pharmaceuticals launches Single Inhaler Triple Therapy AIRZ-FF for COPD

11 May 2020 Evaluate

Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD).

This new triple therapy innovation offers significant bronchodilation (making breathing easier), reduces risk of severe attacks, and eliminates dependence on multiple inhalers. The reduction in risk of severe attacks decreases the requirement for hospitalization, a benefit of high significance in current prevailing situation.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×